Impact of bile acids on the growth of human cholangiocarcinoma via FXR

被引:82
作者
Dai, Jiaqi [1 ]
Wang, Hongxia [2 ]
Shi, Yihui [3 ]
Dong, Ying [4 ]
Zhang, Yinxin [1 ]
Wang, Jian [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Renji Hosp, Div Gen Surg, Shanghai 200127, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Shanghai Renji Hosp, Div Oncol, Shanghai 200127, Peoples R China
[3] SRI Int, Biosci Div, Menlo Pk, CA 94025 USA
[4] Shanghai Jiao Tong Univ, Sch Med, Shanghai Renji Hosp, Div Endocrinol, Shanghai 200127, Peoples R China
关键词
FARNESOID-X-RECEPTOR; BREAST-CANCER; CELL-GROWTH; ACTIVATION; EXPRESSION; LIVER; TRANSCRIPTION; INHIBITORS; RELEVANCE; LIGANDS;
D O I
10.1186/1756-8722-4-41
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: The objective of the study was to investigate the effect of different types of bile acids on proliferation of cholangiocarcinoma and the potential molecular mechanisms. Methods: PCR assay and Western blot were performed to detect the expression of farnesoid x receptor (FXR) in mRNA and protein level. Immunohistochemical analysis was carried out to monitor the expression of FXR in cholangiocarcinoma tissues from 26 patients and 10 normal controls. The effects on in vivo tumor growth were also studied in nude mouse model. Results: Free bile acids induced an increased expression of FXR; on the contrary, the conjugated bile acids decreased the expression of FXR. The FXR effect has been illustrated with the use of the FXR agonist GW4064 and the FXR antagonist GS. More specifically, when the use of free bile acids combined with FXR agonist GW4064, the tumor cell inhibitory effect was even more pronounced. But adding FXR antagonist GS into the treatment attenuated the tumor inhibitory effect caused by free bile acids. Combined treatment of GS and CDCA could reverse the regulating effect of CDCA on the expression of FXR. Administration of CDCA and GW 4064 resulted in a significant inhibition of tumor growth. The inhibitory effect in combination group (CDCA plus GW 4064) was even more pronounced. Again, the conjugated bile acid-GDCA promoted the growth of tumor. We also found that FXR agonist GW4064 effectively blocked the stimulatory effect of GDCA on tumor growth. And the characteristic and difference of FXR expressions were in agreement with previous experimental results in mouse cholangiocarcinoma tissues. There was also significant difference in FXR expression between normal and tumor tissues from patients with cholangiocarcinoma. Conclusions: The imbalance of ratio of free and conjugated bile acids may play an important role in tumorigenesis of cholangiocarcinoma. FXR, a member of the nuclear receptor superfamily, may mediate the effects induced by the bile acids.
引用
收藏
页数:8
相关论文
共 31 条
[1]
Bile acids as endogenous etiologic agents in gastrointestinal cancer [J].
Bernstein, Harris ;
Bernstein, Carol ;
Payne, Claire M. ;
Dvorak, Katerina .
WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (27) :3329-3340
[2]
The clinical potential of microRNAs [J].
Budhu, Anuradha ;
Ji, Junfang ;
Wang, Xin W. .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
[3]
Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line [J].
Burnat, Grzegorz ;
Rau, Tilman ;
Elshimi, Esam ;
Hahn, Eckhart Georg ;
Konturek, Peter Christopher .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (12) :1460-1465
[4]
Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways [J].
Debruyne, PR ;
Bruyneel, EA ;
Karaguni, IM ;
Li, X ;
Flatau, G ;
Müller, O ;
Zimber, A ;
Gespach, C ;
Mareel, MM .
ONCOGENE, 2002, 21 (44) :6740-6750
[5]
Activation of the interleukin-6/STAT 3 antiapoptotic pathway in esophageal cells by bile acids and low pH: Relevance to Barrett's esophagus [J].
Dvorak, Katerina ;
Chavarria, Melissa ;
Payne, Claire M. ;
Ramsey, Lois ;
Crowley-Weber, Cara ;
Dvorakova, Barbora ;
Dvorak, Bohuslav ;
Bernstein, Harris ;
Holubec, Hana ;
Sampliner, Richard E. ;
Bernstein, Carol ;
Prasad, Anil ;
Green, Sylvan B. ;
Garewal, Harinder .
CLINICAL CANCER RESEARCH, 2007, 13 (18) :5305-5313
[6]
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy [J].
Fremin, Christophe ;
Meloche, Sylvain .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
[7]
Farnesoid X receptor activates transcription of the phospholipid pump MDR3 [J].
Huang, L ;
Zhao, A ;
Lew, JL ;
Zhang, T ;
Hrywna, Y ;
Thompson, JR ;
de Pedro, N ;
Royo, I ;
Blevins, RA ;
Peláez, F ;
Wright, SD ;
Cui, JS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (51) :51085-51090
[8]
Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology [J].
Javle, Milind ;
Hsueh, Chung-Tsen .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
[9]
Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation [J].
Journe, Fabrice ;
Laurent, Guy ;
Chaboteaux, Carole ;
Nonclercq, Denis ;
Durbecq, Virginie ;
Larsimont, Denis ;
Body, Jean-Jacques .
BREAST CANCER RESEARCH AND TREATMENT, 2008, 107 (01) :49-61
[10]
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine [J].
Kim, Insook ;
Ahn, Sung-Hoon ;
Inagaki, Takeshi ;
Choi, Mihwa ;
Ito, Shinji ;
Guo, Grace L. ;
Kliewer, Steven A. ;
Gonzalez, Frank J. .
JOURNAL OF LIPID RESEARCH, 2007, 48 (12) :2664-2672